To recover your password please fill in your email address
Please fill in below form to create an account with us
A Phase II randomised placebo-controlled, double blind, multisite study of Acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive High Grade Glioma requiring treatment with Dexamethasone – The ACED trial
See ANZCTR for full trial details >
|
Trial Summary: |
The purpose of this clinical research study is to determine whether adding acetazolamide to dexamethasone improves patient outcome and lessens corticosteroid side-effects in patients with recurrent or progressive high grade glioma. This study will also describe the possible side effects of both dexamethasone and acetazolamide on your quality of life. |
|
Supported By: |
Perpetual via CBCF; Cancer Australia, COGNO, NHMRC CTC |
|
Eligibility: |
Recurrent and/or progressive HGG patients who require recommencement of dexamethasone or dose increase due to progressive raised ICP regardless of aetiology |
|
Registration ID: |
ACTRN12615001072505 |
|
Participation: |
Australia |
|
Australian Lead Group: |
COGNO, NHMRC CTC |
|
Status: |
Complete |
|
Activation Date: |
24/02/2016 |
|
Chairs: |
Prof Meera Agar |
|
Contact: |